Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

» NAS:DYAX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-28)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

DYAX Guru Trades in Q3 2015

Steven Cohen 10,600 sh (New)
Jim Simons 343,308 sh (+103.74%)
Ken Fisher 185,375 sh (+1.60%)
PRIMECAP Management 10,617,860 sh (unchged)
Chuck Royce Sold Out
» More
Q4 2015

DYAX Guru Trades in Q4 2015

Mario Gabelli 187,150 sh (New)
Jeremy Grantham 546,377 sh (New)
Ken Fisher 185,375 sh (unchged)
Jim Simons Sold Out
Steven Cohen Sold Out
PRIMECAP Management 10,482,860 sh (-1.27%)
» More
Q1 2016

DYAX Guru Trades in Q1 2016

PRIMECAP Management 10,482,860 sh (unchged)
Jeremy Grantham Sold Out
Mario Gabelli Sold Out
Ken Fisher Sold Out
» More
Q2 2016

DYAX Guru Trades in Q2 2016

PRIMECAP Management 10,482,860 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with DYAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Traded in other countries:DY8.Germany,

Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.



Buy Back


Valuation & Return


More Statistics

Revenue (TTM) (Mil) $97.55
EPS (TTM) $ -0.21
Short Percentage of Float2.93%
52-Week Range $14.06 - 38.56
Shares Outstanding (Mil)147.18

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue (Mil $) 98 116 115 372
EPS ($) -0.26 -0.20 -0.23 1.05
EPS w/o NRI ($) -0.26 -0.20 -0.23 1.05
EPS Growth Rate
(3Y to 5Y Estimate)
Dividends Per Share ($)
» More Articles for NAS:DYAX


Articles On GuruFocus.com
Mario Gabelli Comments on Dyax Corp May 03 2016 
The Gabelli ABC Fund 1st Quarter Shareholder Commentary May 03 2016 
Meridian Funds Comments on Dyax Corp Mar 07 2016 
Meridian Growth Fund Semi-Annual Letter to Shareholders Mar 07 2016 
Mario Gabelli Comments on Dyax Corp Jan 29 2016 
Chuck Royce Makes Big Gains on Divestitures Jan 03 2016 
Voltari Corp. (VLTC) Under Carl Icahn Umbrella, Dyax Corp. (DYAX) Potential Angioedema Preventive Tr Apr 01 2015 
Weekly CFO Buys Highlight: DYAX, IBI, FARM, TAP, DBM Mar 19 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 

More From Other Websites
Peter Kolchinsky Is Betting Big On Achillion Pharmaceuticals, Inc. (ACHN), Wave Life Sciences (WVE)... Feb 25 2016
Here Are The Most Notable Insider Transactions Hitting The Market Jan 26 2016
Shire stays mum on Burlington facilities, employees in wake of Dyax acquisition Jan 25 2016
DYAX CORP Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of... Jan 22 2016
Shire Completes Acquisition of Dyax Jan 22 2016
Shire Completes Acquisition of Dyax Jan 22 2016
Technical Scrutiny on Biotechnology Stocks -- Gilead Sciences, Sarepta Therapeutics, Dyax Corp., and... Jan 21 2016
3 Stocks Making New 52-Week Highs Jan 20 2016
The Zacks Analyst Blog Highlights: ALPS Medical Breakthroughs ETF, Anacor Pharmaceuticals, Dyax,... Dec 29 2015
5 Top Performing Stocks of the Top ETF of 2015 Dec 28 2015
Here are the 20 top-performing stocks in Mass. for 2015 Dec 14 2015
DYAX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 11 2015
Dyax Corp. Sets January 21, 2016 As Date of Special Stockholder Meeting To Vote On Its Proposed... Dec 11 2015
Dyax Corp. Sets January 21, 2016 As Date of Special Stockholder Meeting To Vote On Its Proposed... Dec 11 2015
DYAX CORP Financials Dec 08 2015
Dyax Corp. Presents Phase 1b DX-2930 Data at the American College of Allergy, Asthma, and Immunology... Dec 08 2015
Dyax Corp. Presents DX-4012 Data at the 2015 American Society of Hematology Annual Meeting Dec 08 2015
Dyax Corp. Announces Early Termination of Hart-Scott-Rodino Waiting Period Dec 08 2015
Dyax Corp. Recognized as a "Top Place to Work" by The Boston Globe for Second Year in a Row Dec 08 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)